Actively Recruiting
Evaluation of sFlt-1/PlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia
Led by Ammar Jassim Abed · Updated on 2026-01-20
120
Participants Needed
1
Research Sites
28 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
his study investigates the effectiveness of three specific biological markers (biomarkers) in the blood-the sFlt-1/PlGF ratio, soluble endoglin (sEng), and osteoprotegerin (OPG)-to better diagnose and monitor preeclampsia. Preeclampsia is a serious pregnancy complication characterized by high blood pressure and potential organ damage that affects 2-8% of pregnancies worldwide
CONDITIONS
Official Title
Evaluation of sFlt-1/PlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pregnant women between 20 and 36 weeks of gestation
- Age between 18 and 45 years
- Attending the antenatal clinic at the study site
You will not qualify if you...
- Chronic hypertension
- Renal disease
- Diabetes mellitus
- Multiple gestations
- Autoimmune disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Bint Al Huda Maternity Hospital
Nasiriyah, Dhi Qar, Iraq, 64001
Actively Recruiting
Research Team
A
Ammar Jassim Abed, MSc
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here